{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CLPT",
  "name": "ClearPoint Neuro, Inc.",
  "url": "https://orbyd.app/dossiers/CLPT/",
  "json_url": "https://orbyd.app/dossiers/CLPT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72 (7/02) but the theme has cooled to maturing, with no dated catalyst inside 30 days except the ~mid-August Q2 print. A base-watch, not a momentum entry.",
  "invalidation_trigger": "A weekly close below $16 loses the post-catalyst breakout shelf (6/18 gap close $16.81) and unwinds the June re-rate; secondary breaks: the AMT-130 Huntington's BLA slips the Q3-2026 window or draws an FDA refuse-to-file, or FY2026 revenue guide is cut below the $52M floor.",
  "catalyst_date": "2026-08-13",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-14",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Price $18.72 (2026-07-02) held the 6/18 gap and sits below both the $22.44 consensus PT. Riley's $30 target — analyst-defined headroom intact; the clean re-entry is a high-teens base breakout on a fresh catalyst or a higher low holding the rising 20-EMA.",
    "Earnings blackout reminder: avoid fresh sizing into the ~mid-August Q2 print for a thesis that is delivery-royalty driven, not earnings-driven.",
    "Master catalyst = uniQure AMT-130 Huntington's BLA, soft Q3-2026 window (disclosed 2026-06-17); FDA accepted 3-yr high-dose data (75% cUHDRS slowing) as primary basis under accelerated approval; confirmatory-study-design alignment must land first, so the filing date is soft.",
    "Trades as a QURE delivery-sympathy proxy — partner-trial and FDA headlines move the tape more than ClearPoint's own fundamentals; size for exogenous headline gaps.",
    "Q2 2026 earnings ~mid-August (est.; Q1 reported 2026-05-13). Cash $35.6M at 3/31/26, ~$8M/qtr burn; Oberland tranches ($25M + $50M, drawable to 2026-12-31) are a debt backstop, but an S-3 shelf on file = equity-raise overhang.",
    "AMT-260 epilepsy is a slow-burn second program: mixed first-cohort data 6/19 (3 of 6 strong responders, 79–100% seizure reduction, no SAEs); higher-dose update not due until H1 2027.",
    "Price reference $18.72 (2026-07-02) is 3+ weeks stale — re-validate against live quotes before acting. Consensus PT avg $22.44; B. Riley Buy PT $30 (2026-06-18).",
    "Q1 2026: record revenue $12.1M (+43% YoY, 16% organic), gross margin 64%, FY2026 guide $52–56M; 175+ global centers, 60+ biopharma partners."
  ],
  "body_markdown": "## Current Thesis\nClearPoint sells the delivery infrastructure for CNS gene therapy — the SmartFlow cannula and MRI/iCT-guided navigation that partner programs use to put a molecule into the brain — so it earns off the build-out regardless of which therapy clears first. The narrative re-rated in mid-June on two uniQure prints, both administered through ClearPoint hardware: a 2026-06-17 plan to file the AMT-130 Huntington's BLA in the Q3-2026 window, and 2026-06-19 first-cohort AMT-260 epilepsy data. Three weeks on, the setup has cooled. The theme registry now tags the name to life-sciences tools/diagnostics alone, the gene-therapy leg having downshifted from accelerating to maturing, and there is no dated company-specific catalyst before the mid-August Q2 print. The last validated tape ($18.72 on 2026-07-02) held the 6/18 gap and modestly extended, which reads as consolidation on the breakout shelf. That makes this a base to watch, not a momentum entry: the binary that drove the re-rate has already printed, and the next hard date is an earnings event the thesis does not depend on.\n\n## Bull Case\n- Q1 2026 record revenue $12.1M, +43% YoY (16% organic), reported 2026-05-13; FY2026 guide reaffirmed at $52–56M; gross margin 64%, up from 60%.\n- uniQure AMT-130 Huntington's: 3-year high-dose data showed 75% slowing of cUHDRS progression versus propensity-matched external controls; in a Type B meeting disclosed 2026-06-17 the FDA accepted that 3-year analysis as the primary basis for an accelerated-approval BLA targeted for the Q3-2026 window, with RMAT, Breakthrough and Fast Track in hand. AMT-130 is administered via ClearPoint navigation/SmartFlow, so a first approved CNS gene therapy seeds a per-procedure delivery line.\n- AMT-260 epilepsy preliminary data (2026-06-19): 3 of 6 low-dose patients posted 79–100% reductions in disabling seizures across months 4–6 with no therapy- or surgery-related SAEs — a second ClearPoint-delivered program stays live.\n- Installed base of 175+ global centers as of the 2026-05-13 update; capital-equipment and software revenue +177% YoY to $1.4M widens the razor base that pulls recurring disposables.\n- 60+ biopharma partners; a 10-year focused-ultrasound development partnership with Sungkyunkwan University (2026-05-27) extends the ecosystem into blood-brain-barrier delivery, and the Velocity Alpha MR surgical drill cleared FDA 510(k) (2026-04-22) and CE Mark (2026-05-13).\n- The Oberland note facility carries additional $25M and $50M tranches drawable before 2026-12-31 — committed capital that lowers the odds of a forced dilutive equity raise.\n- B. Riley kept a Buy and lifted its target to $30 on 2026-06-18; the 3-analyst average target is $22.44. The last print of $18.72 (2026-07-02) sits under both, leaving analyst-defined headroom intact.\n\n## Bear Case\n- The catalysts that mattered have already printed: the AMT-130 BLA plan (2026-06-17) and AMT-260 data (2026-06-19) are public, the theme has downshifted to maturing, and no dated company-specific catalyst falls inside the next 30 days.\n- The AMT-260 read was thin — 3 of 6 low-dose patients responded strongly, and the higher-dose cohort update is not due until H1 2027, a long wait for the next data point.\n- The FDA still has to align with uniQure on confirmatory-study design (a concurrent standard-of-care control rather than a sham procedure) before the BLA — a gating step that can push a soft Q3-2026 filing further right.\n- Cash was $35.6M at 3/31/26 against ~$8M/quarter operating burn; an S-3 shelf is on file, so equity-raise optionality is a standing overhang even with the Oberland debt tranches available.\n- The name trades as a uniQure sympathy proxy — the 6/18 +26% gap to a $16.81 close came off partner news, not ClearPoint's own results — so a QURE disappointment or FDA setback hits this tape harder than the delivery fundamentals justify.\n- The mid-August Q2 print is a binary the thesis does not require, and stepping in ahead of it stacks earnings risk on top of an already-maturing setup.\n\n## Setup & Price Structure\n- Most recent validated print $18.72 (2026-07-02); this reference is now 3+ weeks old and should be re-checked against live quotes before acting on any level here.\n- Structure: the 2026-06-18 session gapped +26% to a $16.81 close on the QURE read, then held and modestly extended above that gap through early July — consolidation on the breakout shelf rather than a distribution top.\n- A weekly close below $16 loses that shelf and unwinds the June re-rate. Overhead reference sits at the $22.44 consensus average and the $30 B. Riley target.\n- Momentum ran hot into the June spike (RSI in the mid-70s on the gap day) and has since had three weeks to cool; a fresh entry no longer rides an accelerating tape, and there is no clean higher-low pullback-to-support trigger on the board yet.\n- Liquidity is small-cap and headline-driven; gaps on partner news are the dominant price mechanism, so any sizing has to assume overnight event risk.\n\n## Catalyst Calendar (next 30 days)\n- ~2026-08-13 (est.): Q2 2026 earnings. Q1 landed 2026-05-13, so the June-quarter report is the one dated event inside the window. Watch the FY2026 $52–56M guide, the gross-margin trend off the Q1 64%, cash burn against the $35.6M base, and any capital-raise language. Binary risk for a thesis that is not earnings-driven — reason to let the print pass rather than enter into it.\n- Q3-2026 (undated, soft): uniQure AMT-130 Huntington's BLA submission — the master catalyst, contingent on FDA confirmatory-study-design alignment. No confirmed date; a formal BLA acceptance would be the re-acceleration trigger.\n- No AMT-260 update expected in-window; the higher-dose epilepsy cohort read is not due until H1 2027.\n\n## What Would Change Our Mind\n- Bearish invalidation: a weekly close below $16 breaks the post-catalyst breakout shelf and unwinds the June re-rate; reinforced if the AMT-130 BLA slips out of the Q3-2026 window or draws an FDA refuse-to-file, or if the FY2026 revenue guide is cut below the $52M floor at the Q2 print.\n- Bullish re-acceleration that would turn a base-watch into an entry: a dated AMT-130 BLA acceptance, a fresh uniQure Huntington's or epilepsy data/regulatory beat, or a Q2 print that raises the FY2026 guide and clears the dilution overhang. Any of these would re-tag the gene-therapy leg toward accelerating and justify sizing up on a clean higher-low.\n\n## Correlation Notes\n- Primary driver is uniQure (QURE): CLPT moves on AMT-130/AMT-260 trial and FDA headlines more than on its own results, so QURE is the leading indicator for this tape.\n- Beta to the broader CNS gene-therapy and life-sciences-tools/diagnostics complex; focused-ultrasound and neuro-delivery peers share the theme.\n- Small-cap medtech liquidity means index and risk-on/risk-off swings amplify single-name gaps; an S-3 shelf on file adds idiosyncratic supply risk on any strength.",
  "first_seen": "2026-06-17",
  "last_analyzed": "2026-07-25T08:22:16+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}